Program
anlotinib
Also written as “Anlotinib”, “AL3818” and “AK104+anlotinib”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Endometrial Neoplasms · Small Cell Lung Carcinoma · Neoplasms · Sarcoma, led by 8 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 311 open or running | phase 3since Dec 30, 2013 | Mar 29, 2013 | none ahead |
| Advenchen Laboratories | 32 open or running | phase 3since Aug 28, 2015 | Sep 26, 2014 | Dec 2027phase 3 · NCT03016819 |
| Advenchen Laboratories Nanjing | 11 open or running | phase 1since Feb 11, 2026 | Feb 11, 2026 | Mar 31, 2027phase 1 · NCT07438886 |
| Advenchen Pharmaceuticals, LLC. | 11 open or running | phase 2since Aug 12, 2026 | Aug 12, 2026 | Sep 1, 2030phase 2 · NCT07811297 |
| Akeso | 10 open or running | phase 2since Nov 23, 2020 | Nov 23, 2020 | none ahead |
| Fosun Pharma | 11 open or running | phase 2since Apr 25, 2026 | Apr 25, 2026 | Jun 2029phase 2 · NCT07562581 |
| Lyvgen Biopharma | 10 open or running | phase 2since Mar 2, 2022 | Mar 2, 2022 | none ahead |
| Shanghai Gopherwood Biotech | 11 open or running | phase 2since Jan 12, 2023 | Jan 12, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 27 studies since Mar 29, 2013.
- Sep 25, 2019Phase 2 study in Gastrointestinal Stromal TumorsSino Biopharmaceutical · NCT04106024 · 60 enrolled · China
- Dec 30, 2019Phase 2 study in Advanced MalignancySino Biopharmaceutical · NCT04216082 · 93 enrolled · China
- Jan 16, 2020Phase 3 study in Extensive Small Cell Lung CancerSino Biopharmaceutical · NCT04234607 · 738 enrolled · China
- Mar 25, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungSino Biopharmaceutical · NCT04325763 · 315 enrolled · China
- Sep 30, 2020Phase 2 study in Advanced Endometrial CancerSino Biopharmaceutical · NCT04574284 · 170 enrolled · China
- Nov 23, 2020Akeso's first study: phase 2 study in NSCLCNew to AkesoAkeso · NCT04646330 · 114 enrolled · China
- Mar 2, 2022Lyvgen Biopharma's first study: phase 2 study in SarcomaNew to Lyvgen BiopharmaLyvgen Biopharma · NCT05301764 · 39 enrolled · China
- Jan 12, 2023Shanghai Gopherwood Biotech's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Shanghai Gopherwood BiotechShanghai Gopherwood Biotech · NCT05715398 · 90 planned
- Jun 17, 2024Phase 3 study in Small Cell Lung Cancer Limited StageSino Biopharmaceutical · NCT06469879 · 358 planned · China
- Jul 11, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungSino Biopharmaceutical · NCT06507891 · 30 enrolled · China
- Feb 11, 2026Advenchen Laboratories Nanjing's first study: phase 1 study in Healthy VolunteerNew to Advenchen Laboratories NanjingAdvenchen Laboratories Nanjing · NCT07438886 · 16 planned · China
- Apr 25, 2026Fosun Pharma's first study: phase 2 study in Neoplasm MetastasisNew to Fosun PharmaFosun Pharma · NCT07562581 · 48 planned · China
- Aug 12, 2026Advenchen Pharmaceuticals, LLC.'s first study: phase 2 study in Endometrial NeoplasmsNew to Advenchen Pharmaceuticals, LLC.Advenchen Pharmaceuticals, LLC. · NCT07811297 · 138 planned · United States
- Nov 16, 2026Primary completion moved from 2027-11 to 2028-12Date moved laterphase 2 · +13 months · NCT07548177
Ahead
- Mar 31, 2027Primary completion: phase 1 study in Healthy VolunteerAdvenchen Laboratories Nanjing · NCT07438886
- Dec 2027Primary completion: phase 3 study in Sarcoma, Alveolar Soft PartAdvenchen Laboratories · NCT03016819
- Jun 2029Primary completion: phase 2 study in Neoplasm MetastasisFosun Pharma · NCT07562581
- Sep 1, 2030Primary completion: phase 2 study in Endometrial NeoplasmsAdvenchen Pharmaceuticals, LLC. · NCT07811297
TargetBeta
“Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| regorafenibrule | Bayer | phase 4 | 40 |
Studies
All 40 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07811297Endometrial Neoplasms · United States | 2 | Not yet recruiting | Advenchen Pharmaceuticals, LLC. | Sep 1, 2030 | 138 |
| NCT07562581Neoplasm Metastasis · China | 2 | Recruiting | Fosun Pharma | Jun 2029 | 48 |
| NCT07438886Healthy Volunteer · China | 1 | Not yet recruiting | Advenchen Laboratories Nanjing | Mar 31, 2027 | 16 |
| NCT06507891Carcinoma, Non-Small-Cell Lung · China | 2 | Terminated | Sino Biopharmaceutical | Aug 25, 2023 | 30 |
| NCT06469879Small Cell Lung Cancer Limited Stage · China | 3 | Not yet recruiting | Sino Biopharmaceutical | Sep 2026 | 358 |
| NCT05715398Carcinoma, Non-Small-Cell Lung | 2 | Not yet recruiting | Shanghai Gopherwood Biotech | Dec 2024 | 90 |
| NCT05301764Sarcoma · China | 2 | Completed | Lyvgen Biopharma | Dec 19, 2025 | 39 |
| NCT04646330NSCLC · China | 2 | Completed | Akeso | Oct 26, 2023 | 114 |
| NCT04574284Advanced Endometrial Cancer · China | 2 | Completed | Sino Biopharmaceutical | Nov 9, 2023 | 170 |
| NCT04325763Carcinoma, Non-Small-Cell Lung · China | 3 | UNKNOWN | Sino Biopharmaceutical | Dec 2022 | 315 |
| NCT04234607Extensive Small Cell Lung Cancer · China | 3 | UNKNOWN | Sino Biopharmaceutical | Dec 2022 | 738 |
| NCT04216082Advanced Malignancy · China | 2 | Completed | Sino Biopharmaceutical | Aug 31, 2014 | 93 |
| NCT04106024Gastrointestinal Stromal Tumors · China | 2 | UNKNOWN | Sino Biopharmaceutical | Oct 30, 2019 | 60 |
| NCT04073550Small Cell Lung Carcinoma · China | 3 | UNKNOWN | Sino Biopharmaceutical | Jul 31, 2021 | 184 |
| NCT04073537Squamous Non-small Cell Lung Cancer · China | 3 | UNKNOWN | Sino Biopharmaceutical | Jul 31, 2021 | 386 |
| NCT03825705Carcinoma, Hepatocellular · China | 2 | UNKNOWN | Sino Biopharmaceutical | Jan 1, 2021 | 60 |
| NCT03527888Bone Neoplasms · China | 2 | UNKNOWN | Sino Biopharmaceutical | Dec 31, 2019 | 40 |
| NCT03457844Gastroenteropancreatic Neuroendocrine Tumor G3 · China | 2 | UNKNOWN | Sino Biopharmaceutical | Aug 30, 2019 | 60 |
| NCT03059797Small Cell Lung Carcinoma · China | 2 | Completed | Sino Biopharmaceutical | Jun 30, 2018 | 120 |
| NCT03016819Sarcoma, Alveolar Soft Part · United States, China, Italy and more | 3 | Recruiting | Advenchen Laboratories | Dec 2027 | 325 |
| NCT02825563Advanced Cancer · China | 1 | Completed | Sino Biopharmaceutical | Aug 15, 2018 | 22 |
| NCT02809534Carcinoma, Hepatocellular · China | 2 | UNKNOWN | Sino Biopharmaceutical | Dec 2017 | 60 |
| NCT02752516Neoplasms · China | 1 | UNKNOWN | Sino Biopharmaceutical | Dec 2017 | 16 |
| NCT02649361Esophageal Squamous Cell Carcinoma · China | 2 | Completed | Sino Biopharmaceutical | Jul 23, 2018 | 164 |
| NCT02622932Advanced Solid Tumors · China | 1 | Completed | Sino Biopharmaceutical | Dec 30, 2016 | 6 |
| NCT02586350Carcinoma, Medullary · China | 3 | Completed | Sino Biopharmaceutical | Sep 30, 2018 | 91 |
| NCT02586337Differentiated Thyroid Cancer · China | 3 | UNKNOWN | Sino Biopharmaceutical | Dec 2019 | 113 |
| NCT02584478Endometrial Neoplasms · United States, China, Italy and more | 3 | Active, not recruiting | Advenchen Laboratories | Oct 2024 | 294 |
| NCT02461407Stomach Neoplasms · China | 3 | UNKNOWN | Sino Biopharmaceutical | Dec 2017 | 378 |
| NCT02449343Sarcoma · China | 3 | UNKNOWN | Sino Biopharmaceutical | Apr 2017 | 233 |
| NCT02388919Carcinoma, Non-Small-Cell Lung · China | 3 | Completed | Sino Biopharmaceutical | Jan 5, 2017 | 439 |
| NCT02332499Colorectal Neoplasms · China | 3 | Completed | Sino Biopharmaceutical | Aug 18, 2016 | 419 |
| NCT02558348Endometrial Neoplasms · United States | 2 | Terminated | Advenchen Laboratories | Feb 14, 2017 | 12 |
| NCT02072044Carcinoma, Renal Cell · China | 2 | UNKNOWN | Sino Biopharmaceutical | Dec 2017 | 60 |
| NCT02072031Anlotinib · China | 2 | UNKNOWN | Sino Biopharmaceutical | Dec 2016 | 133 |
| NCT02029209Carcinoma, Non-Small-Cell Lung · China | 3 | UNKNOWN | Sino Biopharmaceutical | Mar 2017 | 110 |
| NCT01924195Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Sino Biopharmaceutical | Mar 2015 | 117 |
| NCT01878448Neoplasms · China | 2 | Completed | Sino Biopharmaceutical | Oct 2015 | 166 |
| NCT01874873Neoplasms · China | 2 | Completed | Sino Biopharmaceutical | Dec 2016 | 58 |
| NCT01833923Advanced Cancer · China | 1 | Completed | Sino Biopharmaceutical | Oct 2015 | 35 |
How it is read
Names in the registry
- “Anlotinib”, 27 entries
- “AL3818”, 5 entries
- “AK104+anlotinib”, 3 entries
- “luvometinib + anlotinib”, 2 entries
- “Anlotinib and 14C-labeled Anlotinib”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 7 studies
- Endometrial Neoplasms, 4 studies
- Small Cell Lung Carcinoma, 4 studies
- Neoplasms, 3 studies
- Sarcoma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.